Special issue: advances in immunology and its applications
Mingshun Han, Hongyan Wang

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topicsvaccines and immunoinformatics approaches · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research
Innate immunity and adaptive immunity play crucial roles in regulating inflammation-related diseases such as tumors, infections, and autoimmune diseases. The interplay between innate immunity and adaptive immunity ensures the maintenance of tissue homeostasis and effective clearance of invading pathogens or tumor cells. However, dysregulation in each type of immune cells or their communications leads to pathological conditions, ranging from chronic inflammation to malignant progression. In recent years, the field of immunology has witnessed a paradigm shift, moving from merely describing immune cell signaling or phenotypes to actively exploring strategies that reshape immune functions for therapeutic benefit.
Exploring effectors or strategies to reshape T cell function for the improved anti-tumor and anti-infection efficacy has emerged as a critical research direction. This includes the development and optimization of chimeric antigen receptor T-cell (CAR-T) therapies for clinical applications. While CAR-T therapy has revolutionized the treatment of hematologic malignancies, its success in solid tumors remains limited. Chen et al. [1] dissect the distinct signaling mechanisms of chimeric antigen receptors (CARs) compared to T cell receptors (TCRs). They elucidate how CAR-T cells, despite overcoming MHC restrictions, encounter significant hurdles such as inefficient tumor infiltration and the hostility of the immunosuppressive tumor microenvironment (TME). To address these challenges, the authors underscore several innovative strategies, such as optimizing receptor clustering to facilitate immune synapse formation and integrating novel co-stimulatory domains to augment therapeutic efficacy in solid tumors.
Moving beyond engineering, fundamental insights into microenvironmental stress and T cell intrinsic signaling are pivotal. While oxidative stress is a well-established concept in the TME, Ji and Xiao [2] draw attention to the phenomenon of “reductive stress”. They explain how a surplus of intracellular reducing agents disrupts redox balance, creating a reductive environment that significantly influences immune cell differentiation and tumor survival. In a complementary study, Shi et al. [3] investigate the intrinsic role of pattern recognition receptor (PRR) signaling within T cells. Although PRRs are historically classified as innate sensors, this review highlights their critical function in adaptive immunity, discussing how T cells utilize PRRs to interpret endogenous danger signals and microbial cues to regulate cytokine release and proliferation. Additionally, Ma et al. [4] provide a comprehensive update on T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), an important immune checkpoint. By detailing its expression profile across T cells, NK cells, and myeloid lineages, they propose that rational combination therapies targeting TIM-3 alongside other checkpoints offer a promising avenue to surmount current resistance mechanisms.
This issue also highlights the regulation of immunity by neurotransmitters and biological rhythms, illustrating the profound integration of the immune system with physiological networks. Fan and Zhao [5] summarize the neurotransmitter-receptor landscape in T cell tumor immunology. They elaborate on how specific neurotransmitters, including glutamate, acetylcholine, GABA, and serotonin, could dictate T cell activation and differentiation within the TME. The authors advocate for targeting these neuro-immune axes, such as through β-blockers or glutamate receptor inhibitors, as a new frontier for enhancing cancer immunotherapy. From a different perspective, Sun et al. [6] assess the influence of circadian rhythms on the TME and immunotherapy outcomes. They present evidence indicating that the efficacy of treatments like immune checkpoint blockade depends on administration timing, suggesting that future clinical protocols should incorporate chronobiology to maximize patient benefit. Further exploring this dimension, Zhao et al. [7] examine the bidirectional circadian dialogue between the host and the gut microbiota. They describe how modern lifestyle factors, such as shift work and irregular dietary habits, disrupt this synchronization, resulting in compromised barrier integrity and systemic metabolic disorders.
This issue also focuses on the function of various innate immune cells, including ILCs, macrophages, and dendritic cells (DCs), as well as their crosstalk with T cells in maintaining homeostasis across lung, gut, and aging contexts. Chen et al. [8] concentrate on Group 2 innate lymphoid cells (ILC2s), which functionally mirror Th2 cells. They underscore the context-specific roles of ILC2s in pulmonary diseases, explaining how these cells react to environmental alarmins such as IL-33 and thymic stromal lymphopoietin (TSLP). The review also discusses targeting ILC2 plasticity as a potential therapeutic intervention for lung inflammation. Recent findings suggest lipid metabolism as a crucial determinant of innate immune function. Huang et al. [9] offer an updated survey of lipid-regulated immunobiology in macrophages, examining how fatty acyl composition and oxidative states drive macrophage polarization and fate changes in the context of cancer. Focusing on the intestinal environment, Wang and Liu [10] investigate the metabolic interplay between DCs and the gut microbiota. They discuss how DCs detect microbial metabolites such as short-chain fatty acids to navigate the delicate equilibrium between immune tolerance and inflammation. Furthermore, Zheng et al. [11] address dysregulated immunometabolism in gut inflammation, exploring how metabolic reprogramming—such as impaired glycolysis or fatty acid oxidation—affects immune cell differentiation in conditions such as inflammatory bowel disease (IBD).
Aging is closely related to immune function. Shen et al. [12] provide the possible mechanisms to understand intestinal “immunosenescence” in the face of an aging population. They analyze the link between immune aging and microbiota dysbiosis in driving chronic inflammation and neurodegenerative diseases, suggesting that dietary and microecological interventions might be instrumental in extending the healthspan of the elderly.
Special thanks are extended to all authors for their contributions, who not only summarize existing knowledge but also offer insightful hypotheses and identify future challenges. These reviews will help us to learn the cutting-edge progress in immunology and its potential application to various kinds of diseases. We hope this special issue serves as a valuable resource for researchers and clinicians, paving the way for the next generation of immunological breakthroughs.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Chen Z Zhou X Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy Acta Biochim Biophys Sin 2026, 58: 3–2410.3724/abbs.2025190 PMC 1286261541132090 · doi ↗ · pubmed ↗
- 2Ji X Xiao G Reductive stress in cancer immunology and targeted therapy Acta Biochim Biophys Sin 2026, 58: 25–3810.3724/abbs.2025173 PMC 1286261740975792 · doi ↗ · pubmed ↗
- 3Shi Y Wang M Dai B Lu X Li S T cell-intrinsic PRR signaling in immunity and pathology Acta Biochim Biophys Sin 2026, 58: 39–4810.3724/abbs.2025227 PMC 1286262041420400 · doi ↗ · pubmed ↗
- 4Ma S Zhu M Ma C Li C Immune checkpoint TIM-3 in tumor immunotherapy Acta Biochim Biophys Sin 2026, 58: 49–6610.3724/abbs.2025235 PMC 1286262241437770 · doi ↗ · pubmed ↗
- 5Fan M Zhao X Role of the neurotransmitter-receptor pathway in T-cell tumor immunology and cancer immunotherapy Acta Biochim Biophys Sin 2026, 58: 67–8910.3724/abbs.2025216 PMC 1286261341306018 · doi ↗ · pubmed ↗
- 6Sun X Qin L Liang X Wang D Circadian rhythm in immunotherapy and cellular therapy: impacts on the tumor microenvironment Acta Biochim Biophys Sin 2026, 58: 90–10510.3724/abbs.2025203 PMC 1286260841261920 · doi ↗ · pubmed ↗
- 7Zhao Z Wu S Wang T Zhao Y Gut microbiota circadian rhythms: a key regulator of immunometabolic homeostasis Acta Biochim Biophys Sin 2026, 58: 106–11910.3724/abbs.2025220 PMC 1286260541311218 · doi ↗ · pubmed ↗
- 8Chen Y Ji X Qiu J Qiu J The context-dependent role of ILC 2s in lung diseases Acta Biochim Biophys Sin 2026, 58: 120–13610.3724/abbs.2025243 PMC 1286260941445394 · doi ↗ · pubmed ↗
